Taltz Dosing for Plaque Psoriasis
For adults with moderate-to-severe plaque psoriasis, start with 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2,4,6,8,10, and 12, then 80 mg every 4 weeks for maintenance. 1
Adult Dosing Regimen
The FDA-approved dosing schedule is straightforward and supported by AAD-NPF guidelines with Grade A recommendations 2:
- Loading dose: 160 mg subcutaneously at Week 0
- Induction phase: 80 mg at Weeks 2,4,6,8,10, and 12
- Maintenance phase: 80 mg every 4 weeks starting at Week 16
Important Dosing Consideration
Some patients may require 80 mg every 2 weeks during maintenance to sustain response 2. This more frequent dosing is particularly relevant for patients with:
- Higher body mass index (OR 1.11 per unit increase) 3
- Prior biologic therapy exposure (OR 2.37) 3
- Inadequate response at the standard every-4-week maintenance interval
Research demonstrates that continuous every-2-week dosing through 52 weeks achieves superior efficacy compared to every-4-week maintenance (PASI 75: 85.9% vs 79.0%, p=0.006) without increased safety concerns 4.
Pediatric Dosing (Ages 6-17 Years)
Weight-based dosing every 4 weeks 1:
| Body Weight | Starting Dose (Week 0) | Maintenance (Every 4 Weeks) |
|---|---|---|
| >50 kg | 160 mg | 80 mg |
| 25-50 kg | 80 mg | 40 mg |
| <25 kg | 40 mg | 20 mg |
This weight-based approach ensures pediatric patients achieve similar drug concentrations (3.20-3.33 μg/mL) as adults (3.48 μg/mL), with comparable or superior efficacy (PASI 90: 81.8% in pediatrics vs 66.6% in adults at Week 12) 5, 6.
Pre-Treatment Requirements
Before initiating Taltz 1:
- Screen for tuberculosis - Do not start with active TB; treat latent TB first
- Complete age-appropriate vaccinations per current immunization guidelines
- Assess for inflammatory bowel disease - Avoid in patients with active or history of IBD 2
Administration Details
- Route: Subcutaneous injection
- Sites: Upper arms, thighs, or any abdominal quadrant (rotate sites)
- Temperature: Allow to reach room temperature for 30 minutes before injection
- Self-administration: Adults may self-inject after training; pediatric patients require healthcare provider or trained caregiver administration 1
Special Populations
Psoriatic arthritis with coexistent plaque psoriasis: Use the adult plaque psoriasis dosing regimen (not the psoriatic arthritis-only regimen) 1. This ensures adequate skin clearance while addressing joint symptoms.
Patients with diabetes or prediabetes: Standard dosing remains effective, though patients with type 2 diabetes may be slower to achieve complete clearance (PASI 100) 7.
Clinical Pearls
- Rapid onset: Clinical responses visible as early as Week 1 8
- High efficacy: Achieves PASI 90 in approximately 70-80% of patients by Week 12 2
- Sustained response: Efficacy maintained or improved through 48-60 weeks 6, 4
- Neutralizing antibodies: Can develop and are associated with reduced drug concentrations and loss of efficacy 2
The dosing regimen is well-established through multiple phase 3 RCTs and real-world evidence, with the every-2-week maintenance option providing flexibility for patients requiring more intensive therapy to maintain optimal disease control.